This IDC Market Perspective provides IDC Health Insights' review of key Q4 2018 IT deals, news, and digital initiatives in the European life sciences industry. In the evolving industry environment in Europe, it is critically important for life sciences companies to closely follow the fast-moving trends and developments to identify favorable opportunities and remain competitive. This is the second in the quarterly series of reports that IDC Health Insights has published following the expansion of its in-depth research coverage of life sciences markets across Europe.
"Enabling drug serialization and traceability was the chief focus of European life sciences companies in the last quarter of 2018 due to the looming February 2019 deadline of the EU's Falsified Medicines Directive. Nevertheless, major life sciences companies have also continued actively looking into the game-changing potential of various digital innovations to differentiate their products with a variety of 'beyond-the-pill' features and services and improve patient outcomes" — Senior Research Analyst Nino Giguashvili, IDC Health Insights Europe